Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Inspire Investing LLC

Inspire Investing LLC lessened its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 4.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 38,410 shares of the biopharmaceutical company’s stock after selling 1,981 shares during the quarter. Inspire Investing LLC’s holdings in Catalyst Pharmaceuticals were worth $802,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in CPRX. SG Americas Securities LLC raised its stake in shares of Catalyst Pharmaceuticals by 276.7% in the fourth quarter. SG Americas Securities LLC now owns 32,812 shares of the biopharmaceutical company’s stock worth $685,000 after purchasing an additional 24,102 shares during the last quarter. Dakota Wealth Management purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth about $236,000. Redhawk Wealth Advisors Inc. purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth about $1,273,000. Richard P Slaughter Associates Inc raised its stake in shares of Catalyst Pharmaceuticals by 1.9% in the fourth quarter. Richard P Slaughter Associates Inc now owns 149,406 shares of the biopharmaceutical company’s stock worth $3,118,000 after purchasing an additional 2,770 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth about $134,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Catalyst Pharmaceuticals stock opened at $22.55 on Friday. The stock has a market capitalization of $2.69 billion, a PE ratio of 19.11, a price-to-earnings-growth ratio of 2.28 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 12 month low of $13.12 and a 12 month high of $24.27. The business has a 50 day simple moving average of $21.79 and a 200-day simple moving average of $20.45.

Analysts Set New Price Targets

CPRX has been the subject of several research analyst reports. Truist Financial raised their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Bank of America reiterated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. StockNews.com cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 11th. Stephens initiated coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price target for the company. Finally, HC Wainwright lifted their price target on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $32.86.

Insider Activity

In other news, Director Molly Harper sold 17,500 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the sale, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 79,500 shares of company stock worth $1,754,140 over the last three months. 11.00% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.